Study of a Quadrivalent Influenza Vaccine Administered Intramuscularly in Children/Adolescents and Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

1,701

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

October 31, 2012

Study Completion Date

December 31, 2012

Conditions
Influenza
Interventions
BIOLOGICAL

Quadrivalent Influenza Vaccine (split virion, inactivated)

0.5 mL, Intramuscular

BIOLOGICAL

Quadrivalent Influenza Vaccine (split virion, inactivated)

0.5 mL, Intramuscular

BIOLOGICAL

Quadrivalent Influenza Vaccine (split virion, inactivated)

0.5 mL, Intramuscular

BIOLOGICAL

2011 to 2012 Trivalent Influenza Vaccine

0.5 mL, Intramuscular

Trial Locations (6)

1781

City of Muntinlupa

2145

Westmead NSW

Unknown

Melbourne

Calamba Laguna City

Malate, Manila

Quezon City

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT01481454 - Study of a Quadrivalent Influenza Vaccine Administered Intramuscularly in Children/Adolescents and Adults | Biotech Hunter | Biotech Hunter